Natus Medical Inc. (BABY) Lowered to “Hold” at Zacks Investment Research
According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “
Separately, Raymond James Financial Inc. raised shares of Natus Medical from a market perform rating to an outperform rating and set a $46.00 price objective for the company in a research report on Tuesday, September 13th.
Natus Medical (NASDAQ:BABY) opened at 39.91 on Wednesday. Natus Medical has a one year low of $29.54 and a one year high of $51.05. The firm’s 50-day moving average is $40.44 and its 200 day moving average is $36.82. The stock has a market cap of $1.29 billion, a P/E ratio of 34.41 and a beta of 0.78.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.03. The business earned $96 million during the quarter, compared to analyst estimates of $92.71 million. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.34 earnings per share. On average, analysts anticipate that Natus Medical will post $1.58 EPS for the current fiscal year.
In related news, insider James B. Hawkins acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 28th. The stock was purchased at an average cost of $38.48 per share, with a total value of $384,800.00. Following the transaction, the insider now directly owns 459,725 shares of the company’s stock, valued at approximately $17,690,218. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.80% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. acquired a new position in shares of Natus Medical during the second quarter valued at $23,534,000. Fiera Capital Corp acquired a new position in shares of Natus Medical during the second quarter valued at $14,075,000. Norges Bank acquired a new position in shares of Natus Medical during the fourth quarter valued at $15,163,000. Penn Capital Management Co. Inc. acquired a new position in shares of Natus Medical during the second quarter valued at $9,979,000. Finally, SG Capital Management LLC increased its position in shares of Natus Medical by 88.6% in the second quarter. SG Capital Management LLC now owns 468,518 shares of the company’s stock valued at $17,710,000 after buying an additional 220,097 shares during the period. 87.92% of the stock is owned by hedge funds and other institutional investors.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.